A5023516148- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Multiple and Secondary Primary Cancers
- Lung Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Radiomics and Machine Learning in Medical Imaging
- interferon and immune responses
- Acute Myeloid Leukemia Research
- RNA modifications and cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Head and Neck Cancer Studies
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- Mosquito-borne diseases and control
- Transportation Safety and Impact Analysis
- Medical Imaging Techniques and Applications
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Colorectal and Anal Carcinomas
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Traffic and Road Safety
The University of Texas MD Anderson Cancer Center
1997-2024
Uppsala University
2021
Nationwide Children's Hospital
2014
Parsons Brinckerhoff
2007
Memorial Sloan Kettering Cancer Center
1997
Leiden University Medical Center
1997
Abstract Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer (NSCLC) and, more recently, first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described. Experimental Design: Using cohorts from The University Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Center databases, we collected clinical data patients treated with osimertinib. Molecular profiling analysis performed at the time...
IntroductionProgrammed death-ligand 1 (PD-L1) expression may vary in different disease sites and at time points of the course. We aimed to investigate PD-L1 heterogeneity its usefulness as a predictive value for immune checkpoint inhibitor (ICI) therapy patients with NSCLC.MethodsPD-L1 was analyzed 1398 NSCLC. The ICIs 398 metastatic NSCLC assessed.ResultsPD-L1 significantly associated biopsy (p = 0.004). Adrenal, liver, lymph node (LN) metastases had highest continuous variable 1% or 50%...
Only around 20-30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availability, and tumour heterogeneity, radiographic images might holistically capture the underlying biology. We aimed to investigate application deep learning on chest CT scans derive an imaging signature response immune checkpoint inhibitors evaluate its added value in...
Abstract Purpose: The optimal systemic treatment for pulmonary large-cell neuroendocrine carcinoma (LCNEC) is still under debate. Previous studies showed that LCNEC with different genomic characteristics might respond differently to chemotherapy regimens. In this study, we sought investigate subtyping using cell-free DNA (cfDNA) analysis in advanced and assess its potential prognostic predictive value. Experimental Design: Tumor cfDNA from 63 patients were analyzed by target-captured...
Methylthioadenosine phosphorylase, an essential enzyme for the adenine salvage pathway, is often deficient (MTAPdef) in tumors with 9p21 loss and hypothetically renders susceptible to synthetic lethality by antifolates targeting de novo purine synthesis. Here we report our single arm phase II trial (NCT02693717) that assesses pemetrexed MTAPdef urothelial carcinoma (UC) primary endpoint of overall response rate (ORR). Three 7 enrolled patients show (ORR 43%). Furthermore, a historic cohort...
Abstract The role of combination chemotherapy with immune checkpoint inhibitors (ICI) (ICI-chemo) over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC) remains underexplored. In this retrospective study 1133 NSCLC patients, treatment ICI-mono vs ICI-chemo associate higher rates early progression, but similar long-term progression-free and overall survival. Sequential concurrent have survival, suggesting no synergism from therapy. Integrative modeling identified PD-L1, disease...
Abstract Purpose: Radiotherapy with or without chemotherapy is a mainstay of treatment for locally advanced non–small cell lung cancer (NSCLC), but no predictive markers are currently available to select patients who will benefit from these therapies. In this study, we investigated the association between alterations in STK11/LKB1, second most common tumor suppressor NSCLC, and response radiotherapy as well potential therapeutic approaches improve outcomes. Experimental Design: We conducted...
BackgroundMajor guidelines do not recommend routine molecular profiling of lung squamous-cell carcinoma (LUSC) because the prevalence actionable alterations is thought to be low. Increased utilization next-generation sequencing (NGS), particularly with cell-free circulating tumor DNA, facilitates reevaluation this premise.Patients and MethodsWe retrospectively evaluated in 2 distinct LUSC cohorts totaling 492 patients. A total 410 consecutive patients stage 3B or 4 were tested a targeted DNA...
<h3>Importance</h3> Consolidative durvalumab after definitive chemoradiation for unresectable locally advanced non–small cell lung cancer (NSCLC) can significantly improve progression-free survival (PFS) and overall (OS), as shown in the PACIFIC trial. However, whether patients with driver variations derive equal benefit from this regimen remains unclear. <h3>Objectives</h3> To compare outcomes of NSCLC without treated regimen. <h3>Design, Setting, Participants</h3> This cohort study...
Abstract Purpose: Ataxia-telangiectasia mutated (ATM) is the most frequently DNA damage repair gene in non–small cell lung cancer (NSCLC). However, molecular correlates of ATM mutations and their clinical implications have not been fully elucidated. Experimental Design: Clinicopathologic genomic data from 26,587 patients with NSCLC MD Anderson, public databases, a de-identified nationwide (US-based) clinicogenomic database (CGDB) were used to assess co-mutation landscape, protein expression,...
MET amplification is a known resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant NSCLC. Dual EGFR-MET inhibition has been reported with success overcoming such and inducing clinical benefit. Resistance mechanisms dual require further investigation characterization.Patients NSCLC both mutation who have received crizotinib, capmatinib, savolitinib, or tepotinib plus osimertinib (OSI) after progression on OSI at MD Anderson Cancer Center were included this...
BackgroundThe survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally advanced head and neck squamous cell carcinoma (LAHNSCC). We previously showed feasibility safety cetuximab-based IC (paclitaxel/carboplatin/cetuximab—PCC, docetaxel/cisplatin/5-fluorouracil/cetuximab—C-TPF) local therapy LAHNSCC. The primary end point this phase II clinical trial with randomization to PCC C-TPF combined patients LAHNSCC stratified human...
Abstract Introduction Immune checkpoint inhibitor (ICI) pneumonitis causes substantial morbidity and mortality. Estimates of real-world incidence reported risk factors vary substantially. Methods We conducted a retrospective review 419 patients with advanced non-small cell lung cancer (NSCLC) who were treated anti-PD-(L)1 or without anti-CTLA-4 therapy. Clinical, imaging, microbiological data evaluated by multidisciplinary adjudication teams. The primary outcome interest was grade ≥2...
Traffic volumes and congestion across Utah have continued to increase in recent years, particularly on arterial streets. This increased traffic volume has amplified the emphasis implementing access management techniques (i.e., raised medians or driveway consolidation) alleviate some of safety concerns associated with To determine benefits provided by Utah, an evaluation performance arterials which been implemented within state was performed. complete evaluation, a unique, yet proven, tool...
PURPOSE Local consolidative therapy (LCT) for patients with synchronous oligometastatic non–small-cell lung cancer is an evolving treatment strategy, but outcomes following LCT stratified by genetic mutations have not been reported. We sought to identify genomic associations overall survival (OS) and progression-free (PFS) these patients. METHODS identified all presenting between 2000 2017 stage IV ≤ 3 metastatic sites. Patients were grouped according mutational statuses. Primary included OS...
9017 Background: Temporal and spatial heterogeneity of PD-L1 has been reported. However, its impact on clinical benefit from immune checkpoint inhibitor (ICI) not clearly defined. Methods: We queried the MD Anderson Lung Cancer GEMINI database compared expression (tumor proportion score by immunohistochemistry using FDA-approved antibodies) in NSCLC specimens different organs at time points. assessed predictive value for ICIs patients with metastatic NSCLC. Results: In 1398 patients, level...
Abstract Purpose: Neoadjuvant chemotherapy prior to definitive surgery has been utilized widely for locally advanced oral squamous cell carcinoma (OSCC). We evaluated neoadjuvant erlotinib with platinum-docetaxel vs. placebo in stage III-IVB OSCC patients. Experimental Design: Patients newly diagnosed III, IVA, IVB (AJCC 7th) amenable surgical resection were included. randomized receive up 3 cycles of concurrent or placebo, followed by surgery. The primary endpoint was major pathologic...